Literature DB >> 25820445

[Molecular diagnostics of non-small cell lung cancer: New markers and technologies].

A Warth1, V Endris, M Kriegsmann, A Stenzinger, R Penzel, N Pfarr, W Weichert.   

Abstract

Lung cancer is the prototypical tumor entity for the development of new diagnostic and individualized therapeutic strategies based on molecular patient stratification. Developments in this field specifically concentrate on predictive biomarkers for the response to conventional therapeutic agents, novel drugs targeting specific mutations and also new immunomodulatory drugs. The multitude of upcoming new predictive biomarkers requires the development and implementation of efficient test strategies and comprehensive technical methods, specifically when tissue restrictions inherent to lung cancer diagnostics are also taken into account. Novel procedures and technical aspects of these issues are discussed in this review.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25820445     DOI： 10.1007/s00292-015-0004-4

Source DB:  PubMed          Journal:  Pathologe        ISSN： 0172-8113            Impact factor:   1.011


  59 in total

1.  Molecular diagnostic profiling of lung cancer specimens with a semiconductor-based massive parallel sequencing approach: feasibility, costs, and performance compared with conventional sequencing.

Authors:  Volker Endris; Roland Penzel; Arne Warth; Alexander Muckenhuber; Peter Schirmacher; Albrecht Stenzinger; Wilko Weichert
Journal:  J Mol Diagn       Date:  2013-08-21       Impact factor: 5.568

2.  Plasma DNA microsatellite panel as sensitive and tumor-specific marker in lung cancer patients.

Authors:  Michèle Beau-Faller; Marie Pierre Gaub; Anne Schneider; Xavier Ducrocq; Gilbert Massard; Bernard Gasser; Marie Pierre Chenard; Romain Kessler; Philippe Anker; Maurice Stroun; Emmanuel Weitzenblum; Gabrielle Pauli; Jean Marie Wihlm; Elisabeth Quoix; Pierre Oudet
Journal:  Int J Cancer       Date:  2003-06-20       Impact factor: 7.396

Review 3.  [Novel morphological and molecular aspects of lung cancer].

Authors:  A Warth; A Stenzinger; W Weichert
Journal:  Pathologe       Date:  2013-09       Impact factor: 1.011

4.  Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies.

Authors:  Arne Warth; Roland Penzel; Regine Brandt; Christine Sers; Jürgen R Fischer; Michael Thomas; Felix J F Herth; Manfred Dietel; Peter Schirmacher; Hendrik Bläker
Journal:  Virchows Arch       Date:  2012-03-15       Impact factor: 4.064

5.  Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy.

Authors:  Oliver Gautschi; Colette Bigosch; Barbara Huegli; Monika Jermann; Arthur Marx; Eveline Chassé; Daniel Ratschiller; Walter Weder; Markus Joerger; Daniel C Betticher; Rolf A Stahel; Annemarie Ziegler
Journal:  J Clin Oncol       Date:  2004-10-15       Impact factor: 44.544

6.  Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.

Authors:  Marcin Imielinski; Alice H Berger; Peter S Hammerman; Bryan Hernandez; Trevor J Pugh; Eran Hodis; Jeonghee Cho; James Suh; Marzia Capelletti; Andrey Sivachenko; Carrie Sougnez; Daniel Auclair; Michael S Lawrence; Petar Stojanov; Kristian Cibulskis; Kyusam Choi; Luc de Waal; Tanaz Sharifnia; Angela Brooks; Heidi Greulich; Shantanu Banerji; Thomas Zander; Danila Seidel; Frauke Leenders; Sascha Ansén; Corinna Ludwig; Walburga Engel-Riedel; Erich Stoelben; Jürgen Wolf; Chandra Goparju; Kristin Thompson; Wendy Winckler; David Kwiatkowski; Bruce E Johnson; Pasi A Jänne; Vincent A Miller; William Pao; William D Travis; Harvey I Pass; Stacey B Gabriel; Eric S Lander; Roman K Thomas; Levi A Garraway; Gad Getz; Matthew Meyerson
Journal:  Cell       Date:  2012-09-14       Impact factor: 41.582

7.  EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype.

Authors:  Arne Warth; Roland Penzel; Heike Lindenmaier; Regine Brandt; Albrecht Stenzinger; Esther Herpel; Benjamin Goeppert; Michael Thomas; Felix J F Herth; Hendrik Dienemann; Philipp A Schnabel; Peter Schirmacher; Hans Hoffmann; Thomas Muley; Wilko Weichert
Journal:  Eur Respir J       Date:  2013-08-29       Impact factor: 16.671

8.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Authors:  Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

9.  Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.

Authors:  Gerold Bepler; Charles Williams; Michael J Schell; Wei Chen; Zhong Zheng; George Simon; Shirish Gadgeel; Xiuhua Zhao; Fred Schreiber; Julie Brahmer; Alberto Chiappori; Tawee Tanvetyanon; Mary Pinder-Schenck; Jhanelle Gray; Eric Haura; Scott Antonia; Juergen R Fischer
Journal:  J Clin Oncol       Date:  2013-05-20       Impact factor: 44.544

10.  Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

Authors:  D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella-Garcia; Stephen B Fox; Gregory J Riely; Benjamin Solomon; Sai-Hong I Ou; Dong-Wan Kim; Ravi Salgia; Panagiotis Fidias; Jeffrey A Engelman; Leena Gandhi; Pasi A Jänne; Daniel B Costa; Geoffrey I Shapiro; Patricia Lorusso; Katherine Ruffner; Patricia Stephenson; Yiyun Tang; Keith Wilner; Jeffrey W Clark; Alice T Shaw
Journal:  Lancet Oncol       Date:  2012-09-04       Impact factor: 41.316
View more
  4 in total

1.  Individualized medicine and demographic change as determining workload factors in pathology: quo vadis?

Authors:  Arne Warth; Albrecht Stenzinger; Mindaugas Andrulis; Werner Schlake; Gisela Kempny; Peter Schirmacher; Wilko Weichert
Journal:  Virchows Arch       Date:  2015-10-24       Impact factor: 4.064

Review 2.  [Pathology of lung cancer].

Authors:  D Theegarten; T Hager
Journal:  Radiologe       Date:  2016-09       Impact factor: 0.635

Review 3.  [Diagnosis, prognosis, and prediction of non-small cell lung cancer. Importance of morphology, immunohistochemistry and molecular pathology].

Authors:  A Warth
Journal:  Pathologe       Date:  2015-11       Impact factor: 1.011

4.  lncRNA-disease association prediction based on latent factor model and projection.

Authors:  Bo Wang; Chao Zhang; Xiao-Xin Du; Jian-Fei Zhang
Journal:  Sci Rep       Date:  2021-10-07       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.